u/IJesusChrist · 288d ago2 prior · awaiting results
NMRA is next!
GLUE has positioned itself in NLRP3 with a different upstream target strategy and stands to benefit from LLY's acquisition of VTYX. As part of the broader pharma ecosystem watching this deal, GLUE should see upside.
Now $11.22as of Oct 21, 4:00 PM ET